September 30, 2025- ZOLL® announced that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, has received premarket approval (PMA) from the U.S. Food and Drug Administration (FDA).
The Zenix monitor/defibrillator is a groundbreaking device that redefines efficiency, clarity, and intelligence in both EMS and hospital settings. Built from years of feedback from customers, Zenix combines intuitive design with powerful functionality to enhance patient care and automate workflows for ease-of-use. Featuring a large, durable touchscreen, Zenix provides critical information when it’s needed. With on-the-fly customization, healthcare professionals can make real-time adjustments, helping them stay in control during high-pressure situations.
Equipped with ZOLL’s innovative Real BVM Help® and exclusive Real CPR Help® technology, Zenix gives healthcare providers real-time clinical feedback to improve ventilation quality and deliver high-quality CPR.1 The advanced technology of Zenix empowers EMS teams and hospital clinicians to make informed, confident decisions and ensure they are delivering exceptional patient care, every time.
The Zenix monitor/defibrillator is available now to customers in the U.S. For more information, call 800.348.9011 or visit www.zoll.com/zenix.